LifeVantage (LFVN) Competitors $13.00 +0.78 (+6.38%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends LFVN vs. KIN, AVEO, PHVS, ANNX, TRML, HUMA, ALGS, ABVX, YMAB, and OCSShould you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Kindred Biosciences (KIN), AVEO Pharmaceuticals (AVEO), Pharvaris (PHVS), Annexon (ANNX), Tourmaline Bio (TRML), Humacyte (HUMA), Aligos Therapeutics (ALGS), ABIVAX Société Anonyme (ABVX), Y-mAbs Therapeutics (YMAB), and Oculis (OCS). These companies are all part of the "medical" sector. LifeVantage vs. Kindred Biosciences AVEO Pharmaceuticals Pharvaris Annexon Tourmaline Bio Humacyte Aligos Therapeutics ABIVAX Société Anonyme Y-mAbs Therapeutics Oculis LifeVantage (NASDAQ:LFVN) and Kindred Biosciences (NASDAQ:KIN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Which has more risk and volatility, LFVN or KIN? LifeVantage has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Kindred Biosciences has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Do institutionals & insiders hold more shares of LFVN or KIN? 35.3% of LifeVantage shares are held by institutional investors. Comparatively, 66.9% of Kindred Biosciences shares are held by institutional investors. 20.7% of LifeVantage shares are held by insiders. Comparatively, 13.7% of Kindred Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer LFVN or KIN? In the previous week, LifeVantage had 17 more articles in the media than Kindred Biosciences. MarketBeat recorded 17 mentions for LifeVantage and 0 mentions for Kindred Biosciences. LifeVantage's average media sentiment score of 0.23 beat Kindred Biosciences' score of 0.00 indicating that LifeVantage is being referred to more favorably in the media. Company Overall Sentiment LifeVantage Neutral Kindred Biosciences Neutral Does the MarketBeat Community believe in LFVN or KIN? Kindred Biosciences received 145 more outperform votes than LifeVantage when rated by MarketBeat users. However, 77.82% of users gave LifeVantage an outperform vote while only 54.30% of users gave Kindred Biosciences an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22177.82% Underperform Votes6322.18% Kindred BiosciencesOutperform Votes36654.30% Underperform Votes30845.70% Which has better valuation & earnings, LFVN or KIN? LifeVantage has higher revenue and earnings than Kindred Biosciences. Kindred Biosciences is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$200.16M0.81$2.94M$0.3240.63Kindred Biosciences$42.16M9.97-$21.80M-$0.55-16.82 Do analysts recommend LFVN or KIN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AKindred Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is LFVN or KIN more profitable? LifeVantage has a net margin of 2.11% compared to Kindred Biosciences' net margin of -529.26%. LifeVantage's return on equity of 29.24% beat Kindred Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage2.11% 29.24% 12.82% Kindred Biosciences -529.26%-54.19%-39.76% SummaryLifeVantage beats Kindred Biosciences on 11 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get LifeVantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.76M$7.02B$5.33B$8.52BDividend Yield1.24%7.92%5.07%4.13%P/E Ratio40.6312.34128.5816.13Price / Sales0.81402.651,490.3793.20Price / Cash14.6647.4339.6234.18Price / Book5.885.604.765.07Net Income$2.94M$153.56M$118.92M$225.46M7 Day Performance-7.74%0.13%0.78%0.54%1 Month Performance13.14%15.20%5.62%3.75%1 Year Performance66.88%41.12%36.67%29.48% LifeVantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifeVantage3.2054 of 5 stars$13.00+6.4%N/A+72.0%$162.76M$200.16M40.63260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageKINKindred BiosciencesN/A$9.25flatN/A+0.0%$420.52M$42.16M-8.9863Analyst ForecastAVEOAVEO PharmaceuticalsN/A$15.00flatN/A+0.0%$521.45M$42.29M-17.86114Analyst ForecastPHVSPharvaris2.058 of 5 stars$21.71+1.8%$33.60+54.8%+42.8%$691.25MN/A-8.4130Upcoming EarningsANNXAnnexon1.457 of 5 stars$7.40-0.5%$15.80+113.5%+203.3%$683.86MN/A-6.0260TRMLTourmaline Bio3.453 of 5 stars$26.59-2.7%$61.00+129.4%+52.7%$681.77MN/A-7.2344HUMAHumacyte3.1748 of 5 stars$5.65+1.1%$10.00+77.0%+170.9%$672.83M$1.57M-4.48150News CoverageALGSAligos Therapeutics4.6842 of 5 stars$8.38-0.2%$75.00+795.0%-49.1%$654.56M$7.97M-0.4190Upcoming EarningsABVXABIVAX Société Anonyme3.3682 of 5 stars$10.30-1.4%$36.50+254.4%+5.2%$648.17MN/A0.0061Positive NewsYMABY-mAbs Therapeutics3.3056 of 5 stars$14.48-1.1%$21.14+46.0%+163.2%$645.37M$84.82M-25.86150Upcoming EarningsNews CoveragePositive NewsOCSOculis2.1656 of 5 stars$15.80-0.9%$29.20+84.8%+96.5%$639.96M$980,000.00-8.232Gap Down Related Companies and Tools Related Companies Kindred Biosciences Competitors AVEO Pharmaceuticals Competitors Pharvaris Competitors Annexon Competitors Tourmaline Bio Competitors Humacyte Competitors Aligos Therapeutics Competitors ABIVAX Société Anonyme Competitors Y-mAbs Therapeutics Competitors Oculis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LFVN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LifeVantage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LifeVantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
